IPO Archives - DelveInsight

IPO

Recent Pharma News
FDA approves Lyrica; CRH Medical purchase Crystal River Anesthesia

Generic Lyrica: FDA nods to first generic alternatives to Pfizer’s LyricaThe U.S. FDA has approved the first generic substitute of Pfizer’s Lyrica (pregabalin) in its commitment to facilitate...


Juvenescence
Juvenescence raises $46M; Brainsway files for IPO; Life Biosciences raises

Anti-aging startup Juvenescence raises USD 46 MillionJuvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the mu...


Juvenescence
Atlas Venture raises; Harpoon files IPO; Boston Scientific bags Millipede

Atlas Venture raises USD 250 Million for investing in later-stageMassachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the VC shop ...


Synthorx needs IPO; Deerfield puts up $80M; SVB remunerates; Celgene’s deal

Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO.  A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but ...


Gilead
Gilead remunerates; Roche taps Halozyme’s drug delivery tech; Orchard Therapeutics prices its IPO

Gilead remunerates USD 50 Million to collaborate with synthetic lethality startup TangoGilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachuse...


Gilead
Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives

Innovent Biologics reaps USD 421 Million by Hong Kong IPO Innovent Biologics got delivered USD 421 million in its IPO. The Suzhou-based unicorn priced 236.35 million shares near the top of the ran...


Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a...

Orchard files for USD173 Million IPO to run pivotal gene therapy trials Orchard Therapeutics, Transatlantic biotech, has filed to raise USD 173 million in an IPO. This will lead it to take three ge...


Johnson & Johnson
Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro ...

Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 MillionHologic, a global champion of women's health based in Massachusetts, United States, is taking possession...


Johnson & Johnson
Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, th...


Johnson & Johnson
4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent Bio...

Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing4D Molecular Therapeutics has uprais...


Editor's Pick
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology ...

Advances in genetics research have sparked a surge in interest in gene therapy in derma...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.